Table of contents
Editorial
The regulator disapproves - p1
doi:10.1038/nbt0108-1
Abstract - The regulator disapproves | Full Text - The regulator disapproves | PDF (110 KB) - The regulator disapproves
News
Merck's HIV vaccine flop brings vectors under closer scrutiny - pp3 - 4
Heidi Ledford
doi:10.1038/nbt0108-3
Full Text - Merck's HIV vaccine flop brings vectors under closer scrutiny | PDF (229 KB) - Merck's HIV vaccine flop brings vectors under closer scrutiny
Fractured European market undermines biosimilar launches - pp5 - 6
Nuala Moran
doi:10.1038/nbt0108-5
Full Text - Fractured European market undermines biosimilar launches | PDF (169 KB) - Fractured European market undermines biosimilar launches
Government report critical of FDA blasted as misleading - p7
Jeffrey L. Fox
doi:10.1038/nbt0108-7
Full Text - Government report critical of FDA blasted as misleading | PDF (67 KB) - Government report critical of FDA blasted as misleading
Cellulosic ethanol booms despite unproven business models - pp8 - 9
Emily Waltz
doi:10.1038/nbt0108-8
Full Text - Cellulosic ethanol booms despite unproven business models | PDF (254 KB) - Cellulosic ethanol booms despite unproven business models
In Brief
News in brief - pp11 - 12
doi:10.1038/nbt0108-11
Profile
Greg Simon - p13
Crispin Littlehales
doi:10.1038/nbt0108-13
Abstract - Greg Simon | Full Text - Greg Simon | PDF (78 KB) - Greg Simon
Data Page
Wage power in the life sciences - p14
Stacy Lawrence
doi:10.1038/nbt0108-14
Full Text - Wage power in the life sciences | PDF (172 KB) - Wage power in the life sciences
News Features
Biotech as Bush bows out - pp15 - 18
Aaron Lorenzo
doi:10.1038/nbt0108-15
Abstract - Biotech as Bush bows out | Full Text - Biotech as Bush bows out | PDF (224 KB) - Biotech as Bush bows out
Shareholders flex their muscles - pp19 - 21
Karl Thiel
doi:10.1038/nbt0108-19
Abstract - Shareholders flex their muscles | Full Text - Shareholders flex their muscles | PDF (172 KB) - Shareholders flex their muscles
Bioentrepreneur
Building a business
Giving patients a say: how to work with patient advocacy groups - pp23 - 26
Anne-Laure Winkler & David Finegold
doi:10.1038/bioe.2007.6
PDF (125 KB) - Giving patients a say: how to work with patient advocacy groups
Opinion and Comment
Correspondence
We speak for small biotech - p27
Stephen A Sherwin
doi:10.1038/nbt0108-27a
Full Text - We speak for small biotech | PDF (137 KB) - We speak for small biotech
We speak for small biotech - pp27 - 28
Johan Vanhemelrijck
doi:10.1038/nbt0108-27b
Full Text - We speak for small biotech | PDF (180 KB) - We speak for small biotech
Where did the scientific method go? - pp28 - 29
Michela Noseda & Gary R McLean
doi:10.1038/nbt0108-28
Full Text - Where did the scientific method go? | PDF (169 KB) - Where did the scientific method go?
Response to Where did the scientific method go? - p29
doi:10.1038/nbt0108-29a
Full Text - Response to Where did the scientific method go? | PDF (124 KB) - Response to Where did the scientific method go?
Ethics of research on human biological materials - pp29 - 30
Laurence Lwoff
doi:10.1038/nbt0108-29b
Full Text - Ethics of research on human biological materials | PDF (140 KB) - Ethics of research on human biological materials
Commentary
Privatizing biomedical research—a 'third way' - pp31 - 36
Ron A Bouchard & Trudo Lemmens
doi:10.1038/nbt0108-31
Abstract - Privatizing biomedical research[mdash]a 'third way' | Full Text - Privatizing biomedical research—a 'third way' | PDF (216 KB) - Privatizing biomedical research—a 'third way'
Features
Chinese health biotech and the billion-patient market - pp37 - 53
Sarah E Frew, Stephen M Sammut, Alysha F Shore, Joshua K Ramjist, Sara Al-Bader, Rahim Rezaie, Abdallah S Daar & Peter A Singer
doi:10.1038/nbt0108-37
Abstract - Chinese health biotech and the billion-patient market | Full Text - Chinese health biotech and the billion-patient market | PDF (516 KB) - Chinese health biotech and the billion-patient market | Supplementary information
Patents
Reach-through claims for drug target patents: Rx for pharmaceutical policy - pp55 - 56
Robert A Bohrer
doi:10.1038/nbt0108-55
Abstract - Reach-through claims for drug target patents: Rx for pharmaceutical policy | Full Text - Reach-through claims for drug target patents: Rx for pharmaceutical policy | PDF (89 KB) - Reach-through claims for drug target patents: Rx for pharmaceutical policy
Recent patent applications in antibodies - p57
doi:10.1038/nbt0108-57
Full Text - Recent patent applications in antibodies | PDF (41 KB) - Recent patent applications in antibodies
News and Views
Simpler and safer cell reprogramming - pp59 - 60
Martin F Pera & Kouichi Hasegawa
doi:10.1038/nbt0108-59
Abstract - Simpler and safer cell reprogramming | Full Text - Simpler and safer cell reprogramming | PDF (627 KB) - Simpler and safer cell reprogramming
See also: Research by Nakagawa et al.
Illuminating the switch in influenza viruses - pp60 - 62
Carole A Bewley
doi:10.1038/nbt0108-60
Abstract - Illuminating the switch in influenza viruses | Full Text - Illuminating the switch in influenza viruses | PDF (730 KB) - Illuminating the switch in influenza viruses
See also: Research by Chandrasekaran et al.
Humanizing mouse thrombi - pp62 - 63
Ingo Ahrens & Karlheinz Peter
doi:10.1038/nbt0108-62
Abstract - Humanizing mouse thrombi | Full Text - Humanizing mouse thrombi | PDF (1,458 KB) - Humanizing mouse thrombi
See also: Research by Chen et al.
Primate therapeutic cloning in practice - pp64 - 65
John Gurdon
doi:10.1038/nbt0108-64
Abstract - Primate therapeutic cloning in practice | Full Text - Primate therapeutic cloning in practice | PDF (862 KB) - Primate therapeutic cloning in practice
Genome resequencing and genetic variation - pp65 - 66
Michael Stratton
doi:10.1038/nbt0108-65
Abstract - Genome resequencing and genetic variation | Full Text - Genome resequencing and genetic variation | PDF (148 KB) - Genome resequencing and genetic variation
Research highlights - p67
doi:10.1038/nbt0108-67
Full Text - Research highlights | PDF (148 KB) - Research highlights
Computational Biology
Commentary
Protein-protein interaction networks and biology—what's the connection? - pp69 - 72
Luke Hakes, John W Pinney, David L Robertson & Simon C Lovell
doi:10.1038/nbt0108-69
Abstract - Protein-protein interaction networks and biology[mdash]what's the connection? | Full Text - Protein-protein interaction networks and biology—what's the connection? | PDF (762 KB) - Protein-protein interaction networks and biology—what's the connection?
Research
Perspective
Allergenicity assessment of genetically modified crops—what makes sense? - pp73 - 81
Richard E Goodman, Stefan Vieths, Hugh A Sampson, David Hill, Motohiro Ebisawa, Steve L Taylor & Ronald van Ree
doi:10.1038/nbt1343
Abstract - Allergenicity assessment of genetically modified crops[mdash]what makes sense? | Full Text - Allergenicity assessment of genetically modified crops—what makes sense? | PDF (358 KB) - Allergenicity assessment of genetically modified crops—what makes sense?
Articles
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags - pp83 - 90
Ximei Qian, Xiang-Hong Peng, Dominic O Ansari, Qiqin Yin-Goen, Georgia Z Chen, Dong M Shin, Lily Yang, Andrew N Young, May D Wang & Shuming Nie
doi:10.1038/nbt1377
Abstract - In vivo: tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags | Full Text - In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags | PDF (555 KB) - In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags | Supplementary information
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo - pp91 - 100
Erik Henke, Jonathan Perk, Jelena Vider, Paola de Candia, Yvette Chin, David B Solit, Vladimir Ponomarev, Luca Cartegni, Katia Manova, Neal Rosen & Robert Benezra
doi:10.1038/nbt1366
Abstract - Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator : in vivo | Full Text - Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo | PDF (688 KB) - Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo | Supplementary information
Letters
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts - pp101 - 106
Masato Nakagawa, Michiyo Koyanagi, Koji Tanabe, Kazutoshi Takahashi, Tomoko Ichisaka, Takashi Aoi, Keisuke Okita, Yuji Mochiduki, Nanako Takizawa & Shinya Yamanaka
doi:10.1038/nbt1374
First paragraph - Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts | Full Text - Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts | PDF (1,078 KB) - Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts | Supplementary information
See also: News and Views by Pera & Hasegawa
Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin - pp107 - 113
Aarthi Chandrasekaran, Aravind Srinivasan, Rahul Raman, Karthik Viswanathan, S Raguram, Terrence M Tumpey, V Sasisekharan & Ram Sasisekharan
doi:10.1038/nbt1375
First paragraph - Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin | Full Text - Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin | PDF (688 KB) - Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin | Supplementary information
See also: News and Views by Bewley
Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies - pp114 - 119
Jianchun Chen, Kui Tan, Hairu Zhou, Hsuan-Fu Lo, Diana Tronik-Le Roux, Robert C Liddington & Thomas G Diacovo
doi:10.1038/nbt1373
First paragraph - Modifying murine von Willebrand factor A1 domain for : in vivo: assessment of human platelet therapies | Full Text - Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies | PDF (333 KB) - Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies | Supplementary information
See also: News and Views by Ahrens & Peter
Microscale culture of human liver cells for drug development - pp120 - 126
Salman R Khetani & Sangeeta N Bhatia
doi:10.1038/nbt1361
First paragraph - Microscale culture of human liver cells for drug development | Full Text - Microscale culture of human liver cells for drug development | PDF (511 KB) - Microscale culture of human liver cells for drug development | Supplementary information
A quantitative analysis of kinase inhibitor selectivity - pp127 - 132
Mazen W Karaman, Sanna Herrgard, Daniel K Treiber, Paul Gallant, Corey E Atteridge, Brian T Campbell, Katrina W Chan, Pietro Ciceri, Mindy I Davis, Philip T Edeen, Raffaella Faraoni, Mark Floyd, Jeremy P Hunt, Daniel J Lockhart, Zdravko V Milanov, Michael J Morrison, Gabriel Pallares, Hitesh K Patel, Stephanie Pritchard, Lisa M Wodicka & Patrick P Zarrinkar
doi:10.1038/nbt1358
Abstract - A quantitative analysis of kinase inhibitor selectivity | Full Text - A quantitative analysis of kinase inhibitor selectivity | PDF (894 KB) - A quantitative analysis of kinase inhibitor selectivity | Supplementary information
Naturejobs
Careers and Recruitment
Executive compensation at private biotech companies: a competitive environment - pp133 - 134
Bruce Rychlik & Mike DiPierro
doi:10.1038/nbt0108-133
Abstract - Executive compensation at private biotech companies: a competitive environment | Full Text - Executive compensation at private biotech companies: a competitive environment | PDF (98 KB) - Executive compensation at private biotech companies: a competitive environment
